Health care stocks were falling hard this afternoon, with the NYSE Health Care Index dropping 1.7% while the SPDR Health Care Select Sector ETF also was down 1.7%.
The Nasdaq Biotechnology index was sinking 2.7% in recent trade.
In company news, electroCore (ECOR) raced nearly 38% higher after the Us Food and Drug Administration granted an emergency use authorization for the company's gammaCore Sapphire CV vagus nerve stimulation therapy in COVID-19 patients with asthma-related dyspnea and reduced airflow. Initial distribution to hospitals and patients at home had been expected to begin Friday.
Tiziana Life Sciences (TLSA) was nearly 52% higher this afternoon, easing from a 146% gain earlier Friday, after the biotechnology company said it has filed a patent application for a nasal formulation of its Foralumab monoclonal antibody. The move follows phase I testing showing Foralumab had positive immunomodulatory effects in patients with COVID-19 by modulating the body's immune system to suppress the cytokine storm often associated with COVID-19.
Gilead Sciences (GILD) fell about 4.3% after the drugmaker reported non-GAAP Q2 net income of $1.11 per share on $5.14 billion in revenue, trailing the Capital IQ consensus expecting a $1.45 per share adjusted profit on $5.3 billion in revenue. Gilead shares also were pressured by reports an international panel of experts told the British Medical Journal the company's remdesivir prospective anti-viral drug needs more testing to determine its efficacy treating COVID-19.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest Markets Videos
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- EXCLUSIVE-Facebook-owner Meta tells hardware staffers to prepare for cutbacks
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling